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Abstract
Introduction Despite the fact that people older than 65 years of
age have the highest incidence of developing breast cancer,
these patients are excluded from clinical trials in most cases.
Furthermore, most physicians tend towards therapy regimens
without the use of dose-dense, highly active taxane-based
treatments because of a lack of data regarding toxicities of these
compounds in older patients.
Methods Pooled side-effect data were analyzed from four
prospective, randomized clinical trials in which patients of
different age groups (< 60 years, between 60 and 64 years, and
> 64 years) with primary breast cancer received taxane-based
chemotherapy.
Results Dose delays, dose reductions, hospitalization, and
therapy discontinuation increased with age. Hematologic
toxicities and some nonhematologic toxicities were generally
more common in older patients. Leucopenia increased from
55.3% in patients aged < 60 years to 65.5% in patients aged >
64 years (P < 0.001), and neutropenia increased from 46.9% to
57.4% (P  < 0.001). There was no difference, however, in
clinically more relevant febrile neutropenia between the different
age groups. Thrombopenia shows a similar age-dependent
increase, whereas there is no difference between the age
groups concerning anemia. Hot flushes and elevated liver
enzymes decreased with increasing age.
Conclusions The present pooled analysis of a substantial
cohort of older primary breast cancer patients demonstrates
that taxane-containing (neo)adjuvant chemotherapy is feasible in
older patients and that toxicity can be reduced by sequential
therapy regimens.
Introduction
The incidence of breast cancer in women aged 65 years and
older is the highest in all age groups. These older patients are
generally underrepresented or even excluded from clinical tri-
als, however, leading to a gap in data about the compliance,
safety, and efficacy of highly active taxane-based treatments in
older patients. From several clinical trials, there is a growing
awareness that older primary breast cancer patients achieve
significant survival benefits with (neo)adjuvant chemotherapy
regimens. Regarding the steady increase of life expectancy
today, this should be considered in treatment of older patients
in clinical routine.
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There is evidence in breast cancer that the use of taxanes in
adjuvant chemotherapy yields a survival benefit – especially
from the PACS 01 study, demonstrating a particular benefit in
women aged 50 years or older [1]. There are relatively few
data, however, on the use of these agents in older patients [2].
Owing to concerns about tolerability, there remains a ten-
dency in clinical routine to use less dose-intensive chemother-
apy in older patients with the avoidance of those agents
perceived to be more toxic. We therefore combined data of
different adjuvant and neoadjuvant trials with taxane-contain-
ing regimens. Here we present the results of the first system-
atic pooled analysis of tolerability data for taxane-based
regimens in older primary breast cancer patients.
Materials and methods
A pooled analysis of four German prospective, randomized
clinical trials, conducted during 1999 to 2005, was per-
formed. These trials included primary breast cancer patients
receiving taxane-containing neoadjuvant or adjuvant chemo-
therapy. The meta-database was closed in October 2006; the
number of patients in the present analysis may therefore differ
from the separate study publications. For every study, how-
ever, the number of patients included in the present analysis
exceeds 75% of those evaluable. Toxicity data from the stud-
ies were analyzed for taxane-containing chemotherapy in older
patients (aged > 64 years) compared with toxicity data from
patients aged < 60 years and those aged 60 to 64 years
treated in the same studies. The treatment regimens of the four
trials included are depicted in Figure 1.
Figure 1
Study design of the four trials Study design of the four trials. CR, complete response; PR, partial response; NC, no clinical response. EC-T, epirubicin, cyclophosphamide followed 
by docetaxel; FEC, 5-fluorouracil, epirubicin, cyclophosphamide; EC-P, epirubicin, cyclophosphamide followed by paclitaxel; AC-T, doxorubicin, 
cyclophosphamide followed by docetaxel; E-P, epirubicin followed by paclitaxel; AT, doxorubicin, docetaxel; TAC, docetaxel, doxorubicin, cyclophos-
phamide; NX, vinorelbine, capecitabine. q2W, every 2 weeks; q3W, every 3 weeks; q4W, every 4 weeks. i.v., intravenously; p.o., per orally; d, day.Available online http://breast-cancer-research.com/content/10/5/R77
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In the ADEBAR trial (NCT00047099), patients (n = 1,106/
1,502) received four cycles of adjuvant chemotherapy either
with epirubicin/cyclophosphamide every 3 weeks followed by
four cycles of docetaxel every 3 weeks, or six cycles of 5-fluor-
ouracil, epirubicin on days 1 and 8 and cyclophosphamide on
days 1 to 14 every 4 weeks [3].
In the ASG 1–3 trial (NCT00668616), patients (n = 772)
received four cycles of adjuvant chemotherapy either with epi-
rubicin/cyclophosphamide every 3 weeks then four cycles of
paclitaxel every 3 weeks, or with four cycles of epirubicin every
2 weeks and then four cycles of paclitaxel every 2 weeks
(unpublished data, Kümmel S. et al).
In the GeparDuo trial (NCT00543829), patients (n = 902)
received four cycles of neoadjuvant chemotherapy with doxo-
rubicin/cyclophosphamide every 3 weeks followed by four
cycles of docetaxel every 3 weeks or four cycles of doxoru-
bicin/docetaxel every 2 weeks [4].
In the GeparTrio trial (NCT00544765), patients (n = 1,988/
2,072) received two cycles of neoadjuvant chemotherapy with
docetaxel/doxorubicin/cyclophosphamide (TAC) followed by
either four cycles of TAC or six cycles of TAC or four cycles of
vinorelbine plus capecitabine every 3 weeks [5,6].
For the purpose of the analysis, chemotherapy regimens were
divided into four chemotherapy schedules: combination tax-
ane schedule, TAC 75/50/600 mg/m2; sequence schedule,
doxorubicin(epirubicin)cyclophosphamide 60(90)/600 mg/m2
followed by docetaxel 100 mg/m2 or paclitaxel 175 mg/m2;
combination dose-dense schedule, dose-dense doxorubicin/
docetaxel 50/75 mg/m2; and sequence dose-dense schedule,
dose-dense epirubicin/dose-dense paclitaxel 120/175 mg/
m2.
Supportive care during the studies
Various strategies for supportive therapy and premedication
were used in the studies analyzed. All patients were given pro-
phylactic 5-HT3 antagonists, however, and all patients receiv-
ing taxane regimens also received dexamethasone. Primary
neutropenia prophylaxis was not administered to patients
receiving nontaxane chemotherapy and was not mandatory for
patients receiving the sequence schedule. All patients receiv-
ing combination dose-dense schedules and sequential dose-
dense schedules received prophylaxis with filgrastim or
lenograstim on days 5 to 10. Among the patients receiving the
combination taxane schedule, 16% received no primary
prophylaxis with granulocyte-colony stimulating factor, 23%
received filgrastim or lenograstim on days 5 to 10, and 61%
received pegfilgrastim on day 2 [7]. No patients receiving the
sequence schedule, the combination dose-dense schedule or
the sequence dose-dense schedule received primary anti-
infective prophylaxis – while among those patients who
received the combination taxane schedule, 44% received no
prophylaxis and 56% received ciprofloxacin on days 5 to 14.
In the GeparTrio study, supportive care changed during the
study from ciprofloxacin alone in the pilot phase to filgrastim or
lenograstim prophylaxis, then to pegfilgrastim and, finally, to
pegfilgrastim plus ciprofloxacin [7].
Data collection and statistical analyses
Data were collected on dose delays/reductions, hospitaliza-
tions, treatment discontinuation, deaths, and hematologic and
nonhematologic toxicity. For hematologic toxicity, not all
records of all cycles in the four studies included the same data
on events: febrile neutropenia (FN) data were recorded for
patients on the TAC regimen; all other patients were consid-
ered to have FN of at least grade 3 in a given chemotherapy
cycle if they had grade 3/4 neutropenia, more than grade 1
fever, and no infection. All FN cases reported as serious
adverse events with severity grade were also considered. In
cycles where at least one of the three parameters (neutrope-
nia, fever, infection) was missing, and FN was not reported in
the serious adverse events description, the cycle was consid-
ered a missing value for FN.
All statistical analyses were exploratory and no adjustments
were made for multiple comparison. Calculations were per-
formed using SPSS 12.0.1 for Windows (SPSS Inc. Chicago,
IL, USA). Grading systems for toxicities in different studies
were checked for consistency and were converted into NCI-
CTCAE 3.0 grades. Pearson's chi-squared test was per-
formed to compare incidences of toxicity endpoints in the
three different age groups of patients.
Results
Across the four studies, 422 patients aged ≥ 65 years (out of
4,227 patients), with a median age of 67 years (range 65 to
80 years), received 1,674 cycles of taxane-containing chemo-
therapy regimens. Furthermore, 3,160 patients aged < 60
years, with a median age of 47 years (range 23 to 59 years),
received 14,146 cycles of taxane-containing chemotherapy
regimens. Across the studies, 2,674 cycles were given to
patients aged between 60 and 64 years. Demographic and
clinical characteristics of the patients who received a taxane-
containing chemotherapy and the summary data for all 'older'
patients (aged > 64 years and aged 61 to 64 years) and
'younger' patients (aged < 60 years) are presented in Table 1.
Dose delays/reductions, hospitalizations, therapy 
discontinuations, and deaths during the trials
Dose delays (evaluated from first taxane cycle in sequential
regimens), reductions, and therapy discontinuation for any rea-
son increased with age (Figure 2).
Overall during the taxane cycles, dose delays were reported in
9.0% of patients younger than 60 years versus 12.6% of
patients aged between 60 and 64 years and 13.7% of
patients aged 65 years and older (P = 0.001). Dose reduc-Breast Cancer Research    Vol 10 No 5    Loibl et al.
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tions were reported in 5.1% of patients aged < 60 years, 6.7%
of patients aged 60 to 64 years, and 8.1% of patients aged ≥
65 years (P = 0.019), hospitalization was reported in 16.0%,
23.4%, and 18.1% (P  < 0.001), treatment discontinuation
was reported in 11.8%, 17.2%, and 18.7% (P < 0.001), and
deaths were reported in 0.2%, 0.3%, and 1.0%, respectively
(Figure 3a).
Overall among taxane schedules, the incidences of dose
delays (13.8%) and of hospitalization (25%) were markedly
higher with the sequence dose-dense schedule (dose-dense
epirubicin/dose-dense paclitaxel regimen) versus other taxane
schedules. There are, however, age-specific differences. The
patient age groups < 60 years and 60 to 64 years performed
similarly, whereas patients older than 64 years had the highest
incidences of dose delays (20%) and hospitalizations (50%)
Table 1
Demographic and clinical characteristics of patients at baseline
Characteristic Age group Total
< 60 years 60 to 64 years > 64 years
Cases
Total 3,160 (100) 645 (100) 422 (100) 4,227 (100)
Receptor status (ER-positive and/or PgR-positive versus both negative)
Positive 1,941 (61.4) 447 (69.3) 278 (65.9) 2,666 (63.1)
Negative 876 (27.7) 144 (22.3) 112 (26.5) 1,132 (28.6)
Unknown 343 (10.9) 54 (8.4) 32 (7.6) 429 (10.1)
Tumor grading
Grade 1 142 (5.1) 29 (5.0) 22 (5.8) 193 (5.2)
Grade 2 1,534 (54.9) 321 (55.6) 224 (59.4) 2,079 (55.5)
Grade 3 1,117 (40.0) 227 (39.3) 131 (34.7) 1,475 (39.4)
Valid 2,793 (88.4) 577 (89.5) 377 (89.3) 3,747 (88.6)
Missing 367 (11.6) 68 (10.5) 45 (10.7) 480 (11.4)
Histological tumor type
Ductal invasive 2,405 (76.1) 459 (71.1) 315 (74.6) 3,179 (75.2)
Lobular invasive 477 (15.0) 127 (19.6) 65 (15.4) 669 (15.8)
Other 233 (7.3) 54 (8.3) 35 (8.2) 322 (7.6)
Valid 3,115 (98.6) 640 (99.9) 415 (98.4) 4,170 (98.7)
Missing 45 (1.4) 5 (0.1) 7 (1.6) 57 (1.3)
Surgery type
Breast-conserving 1935 (61.2) 381 (59.0) 228 (54.0) 2,544 (60.1)
Mastectomy 961 (30.4) 216 (33.4) 161 (38.1) 1,338 (31.6)
Valid 2,896 (91.6) 597 (92.5) 389 (92.1) 3,882 (91.8)
Missing 264 (8.3) 48 (7.4) 33 (7.8) 345 (8.1)
Age median (years) 47 62 67 51
Age range (years) 23 to 59 60 to 64 65 to 80 23 to 80
Data presented as n (%). All percentage values are valid. ER, estrogen receptor; PgR, progesterone receptor.
Figure 2
Dose reduction, dose delay, hospitalization, therapy discontinuation,  and death per patient, versus age group Dose reduction, dose delay, hospitalization, therapy discontinuation, 
and death per patient, versus age group.Available online http://breast-cancer-research.com/content/10/5/R77
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with the combination dose-dense schedule (dose-dense dox-
orubicin/docetaxel) (Figure 3b,c,d).
Hematological toxicity
In older patients versus younger patients, the per-patient inci-
dences of grade 3 to grade 4 hematologic adverse events
generally increased with age (Figure 4). Leucopenia increased
from 55.3% in patients < 60 years old to 65.5% in patients >
64 years old (P < 0.001), and neutropenia increased from
46.9% to 57.4% (P < 0.001). There was no difference, how-
ever, in FN between the different age groups.
For taxane therapy, the incidences of grade 3 to grade 4 leu-
copenia were all statistically significantly different per patient
between the age groups and for docetaxel-treated patients (P
< 0.001), whereas for paclitaxel-treated patients an age differ-
ence was only seen for leucopenia (Table 2). Overall there was
no age difference in developing FN. In patients younger than
60 years of age FN was only significantly more common in the
docetaxel-containing regimen, whereas there was no differ-
ence between the docetaxel and paclitaxel regimen in patients
older than 60 years. Anemia and thrombopenia were signifi-
cantly more common in the paclitaxel-containing regimen but
only in the age group below 60 years of age. The rate of throm-
bopenia increased with age, whereas there is no age differ-
ence with anemia.
Among taxane schedules, the taxane combination (TAC) was
overall associated with the highest incidence of hematologic
toxicity, and the dose-dense paclitaxel part of the sequence
dose-dense schedule with the lowest incidence (Table 3). For
the TAC regimen, grade 3 to grade 4 leucopenia was reported
in 57.3% of patients < 60 years old, 65.3% for the patient
group between 60 and 64 years old, and 64.9% for the
patients older than 64 years. Similar results are presented for
grade 3 to grade 4 neutropenia in 37.5%, and 56.7%, and
Figure 3
Dose reduction, dose delay, hospitalization, therapy discontinuation, and death versus schedule Dose reduction, dose delay, hospitalization, therapy discontinuation, and death versus schedule. (a) For all patients. (b) For patients younger than 
60 years old. (c) For patients aged 60 to 64 years. (d) For patients older than 64 years of age.Breast Cancer Research    Vol 10 No 5    Loibl et al.
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55.2% and for FN in 9.3%, 11.3%, and 14.3% for the different
age groups, respectively. Thrombopenia shows a similar age-
dependent increase, whereas there is no difference between
the age groups concerning anemia.
For the dose-dense doxorubicin/docetaxel regimen, grade 3 to
grade 4 leucopenia was reported in 50.2%, 61.3%, and
62.5% of patients in the age groups < 60 years, 60 to 64
years and > 64 years. There was no difference between the
age groups for neutropenia, FN, and anemia and thrombope-
nia grade 3 to grade 4.
In contrast to the combination schedules, the highest inci-
dence of grade 3 to grade 4 toxicity in the sequence sched-
ules occurred for neutropenia, which was reported in 65.5%
of patients older than 64 years when treated with the nontax-
ane-containing regimen (epirubicin/cyclophosphamide or dox-
orubicin/cyclophosphamide). The sequential paclitaxel
regimen was also comparatively well tolerated – especially,
the sequential dose-dense paclitaxel schedule had signifi-
cantly fewer toxicity cases compared with the epirubicin dose-
dense schedule, with a peak incidence of 8.7% for grade 3 to
grade 4 neutropenia per patient (with no cases of FN
reported) in the age group younger than 60 years.
Nonhematologic toxicity
Not all of the nonhematologic toxicity data were consistently
recorded for all chemotherapy regimens and cycles in the
trials. The nonhematologic toxicity associated with taxane
chemotherapy is summarized in Table 4.
In older patients versus younger patients there were signifi-
cantly higher incidences (P < 0.05) of grade 3 to grade 4
fatigue (14.5% in patients aged < 60 years versus 19.5% in
patients aged 60 to 64 years versus 23.5% in patients aged >
64 years), grade 1 to grade 3 loss of appetite (67.0% versus
73.8% versus 84.4%, respectively), grade 1 to grade 4 nau-
sea and vomiting (77.5% versus 79.3% versus 85.5%,
respectively), grade 1 to grade 4 diarrhea (40.6% versus
42.2% versus 50.6%, respectively), and raised creatinine lev-
els grade 1 to grade 4 (3.4% versus 6.3% versus 7.8%,
respectively) with the docetaxel regimen with increasing age.
With paclitaxel, grade 3 to grade 4 mucositis (1.6% versus
5.9% versus 6.3%, respectively) and raised creatinine levels
grade 1 to grade 4 (81.3% versus 4.2% versus 7.0%, respec-
tively) significantly increased with age. Infection with neutrope-
nia grade 1 to grade 4 overall was statistically significantly
increased with age.
Conversely, there was a significantly higher incidence of grade
1 to grade 3 hot flushes (64.6% versus 59.1% versus 51.1%,
P = 0.031) and grade 1 to grade 4 changes in liver enzymes
(53.5% versus 50.3% versus 42.9%, P < 0.001) in younger
patients versus older patients.
Discussion
There is a growing awareness that age per se is a less impor-
tant determinant of choice of therapy concepts and outcome
in older cancer patients than physical status, functional status,
and mental/emotional status. Indeed, it is becoming more and
more evident that older, but otherwise healthy, patients with
primary breast cancer can accrue the same benefits from
standard chemotherapy as younger patients – especially when
regarding the steady increase in life expectancy and quality of
life in western societies. The clinical assumption that most
older patients are too frail to receive standard chemotherapy –
reflected in, for example, less use of adjuvant chemotherapy in
older breast cancer patients [8-10] – is being challenged
[11,12]. There is a paucity of published data from chemother-
apy trials comparing older with younger cancer patients, how-
ever, which has hampered efforts to improve treatment
strategies for this population. This lack of data arises from the
common underrepresentation, if not routine exclusion, of older
patients from many clinical trials [13-15]. Additionally, there
are pharmacokinetic data demonstrating that both taxanes can
be used in older patients without dose modifications but in the
case of an impaired liver function neither paclitaxel nor
docetaxel should be applied due to their high liver metaboliza-
tion [16-18].
The present analysis constitutes the largest pooled analysis to
date of the use of taxanes in older patients with primary breast
cancer. The incidences of dose delays, dose reductions, treat-
Figure 4
Incidences of grade 3 and grade 4 hematologic adverse events versus  age group Incidences of grade 3 and grade 4 hematologic adverse events versus 
age group. Leucopenia: age <60 years, n = 1,730; age between 60 
and 64 years, n = 406; age >64 years, n = 272 (P < 0.001). Neutrope-
nia: age <60 years, n = 1,152; age between 60 and 64 years, n = 326; 
age >64 years, n = 225 (P < 0.001). Febrile neutropenia: age <60 
years, n = 181; age between 60 and 64 years, n = 43; age >64 years, 
n = 29 (P = 0.430). Anemia: age <60 years, n = 97; age between 60 
and 64 years, n = 16; age >64 years, n = 14 (P = 0.674). Thrombope-
nia: age <60 years, n = 70; age between 60 and 64 years, n = 14; age 
>64 years, n = 21 (P = 0.002).Available online http://breast-cancer-research.com/content/10/5/R77
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ment discontinuations, and hospitalizations all increased with
age. With regard to taxane therapy, the combination dose-
dense doxorubicin/docetaxel schedule was the most problem-
atic overall, with a particularly high incidence of hospitaliza-
tions compared with other schedules. One cannot conclude,
however, that nontaxane therapies are the preferred option. In
a previous analysis of the data, the regimen of 5-fluorouracil,
epirubicin on days 1 and 8 and cyclophosphamide on days 1
to 14 [19] was by far the most toxic regimen overall [20].
Amongst the taxane schedules, TAC was overall associated
with the highest incidence of toxicity. In our analysis, paclitaxel
had significantly less hematologic toxicity compared with
docetaxel – which is consistent with data from a prospective
adjuvant trial directly comparing those taxanes [21]. Moreover,
in an adjuvant anthracycline/taxane sequential regimen,
weekly paclitaxel shows the same efficacy as docetaxel [21].
This might therefore be the preferred taxane regimen, at least
for older patients. The relatively low incidence of hematologic
toxicity, with the exception of low-grade anemia, with the
sequence dose-dense schedule is notable and may reflect the
sequential dosing schedule and the obligatory use of granulo-
cyte-colony stimulating factor therapy.
With regard to higher grade nonhematologic toxicity, mucosi-
tis, loss of appetite, infection with neutropenia, and fatigue
were more common with increasing age. In patients treated
with docetaxel, skin changes of grade 3 to grade 4 increased
with age.
Analysis of the data by age shows that there was generally a
higher incidence of dose delays/reductions, hospitalizations
and therapy discontinuations, of hematologic toxicity, and of
some nonhematologic toxicity such as loss of appetite and
grade 3 to grade 4 fatigue and mucositis in 'older' versus
younger patients. One might argue that such an age split in
Table 2
Incidence of grade 3 to grade 4 hematologic toxicity, per age interval and per taxane
Docetaxel Paclitaxel Total P value, docetaxel versus paclitaxel
Leukopenia
Patients aged < 60 years 1,534 (59.6) 196 (35.3) 1,730 (55.3) <0.001
Patients aged 60 to 64 years 351 (68.3) 55 (45.8) 406 (64.0) <0.001
Patients aged > 64 years 234 (69.2) 38 (49.4) 272 (65.5) 0.001
P value <0.001 0.011 <0.001
Neutropenia
Patients aged < 60 years 926 (47.4) 226 (44.8) 1,152 (46.9) 0.321
Patients aged 60 to 64 years 273 (57.6) 53 (48.6) 326 (55.9) 0.111
Patients aged > 64 years 190 (59.2) 35 (49.3) 225 (57.4) 0.164
P value <0.001 0.643 <0.001
Febrile neutropenia
Patients aged <60 years 179 (7.2) 2 (0.4) 181 (6.1) <0.001
Patients aged 60 to 64 years 40 (8.1) 3 (2.8) 43 (7.2) 0.085
Patients aged > 64 years 28 (8.7) 1 (1.4) 29 (7.4) 0.061
P value 0.560 0.049 0.430
Anemia
Patients aged < 60 years 57 (2.2) 40 (7.2) 97 (3.1) <0.001
Patients aged 60 to 64 years 12 (2.3) 4 (3.3) 16 (2.5) 0.756
Patients aged > 64 years 12 (3.6) 2 (2.6) 14 (3.4) 0.946
P value 0.315 0.110 0.674
Thrombopenia
Patients aged < 60 years 44 (1.7) 26 (4.7) 70 (2.3) <0.001
Patients aged 60 to 64 years 13 (2.5) 1 (0.8) 14 (2.2) 0.432
Patients aged > 64 years 21 (6.2) 0 (0.0) 21 (5.1) 0.050
P value <0.001 0.025 0002
Data presented as n (%). All percentage values are valid. P values all for incidence of difference between age groups.Breast Cancer Research    Vol 10 No 5    Loibl et al.
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three different groups is artificial, that a higher age should be
considered to constitute 'older' patients, and that simple dis-
crimination by age alone does not account for other factors
(such as physical status). Nevertheless, these data provide an
important insight into the acceptable tolerability of chemother-
apy in older patients with primary breast cancer and could be
confirmed by data from patients with ovarian cancer [13].
The patient cohort for the four trials analyzed reflects clinical
trial routine at that time and substantiates findings from other
studies [22-24], demonstrating that – even if the trials had no
upper age limit – older patients were generally included less
frequently or not included. This may have changed since the
data published by Muss and colleagues [25], which showed
that the benefit from chemotherapy did not differ across age
groups although treatment-related mortality was higher (1.5%
versus 0.42%) in the group aged > 65 years.
While the present analysis has provided a wealth of important
new data, it is important to acknowledge its limitations –
namely, the post hoc nature of the analysis, a relative paucity
of patients aged > 70 years, the probability that the patient
population is not representative of older patients as a whole
due to general exclusion of patients with comorbidities from
clinical trials, and the lack of any exact prognostic score such
as the Charlson score for enrolled older patients. Heterogene-
ous use of growth factors between the studies analyzed and
their chemotherapy regimens may also have had an impact on
some of the variables assessed.
In summary, our analysis indicates that – with pretreatment
older assessment and appropriate supportive care such as
granulocyte-colony stimulating factor therapy for neutropenia
prophylaxis – older patients can be considered for taxane ther-
apy and the maintenance of dose intensity should be feasible.
Older patients generally have an increased susceptibility for
myelotoxicity [26-28]; this has recently been acknowledged by
the updated EORTC guidelines, which recommend general
use of granulocyte-colony stimulating factor prophylaxis if the
risk of FN is ≥ 20% and risk-adapted use in cases where the
FN risk is between 10% and 20% [26]. Our findings are in
accordance with other studies that have, for example, sug-
gested docetaxel therapy as a viable treatment option in older
cancer patients [29,30]. In particular, sequential therapy
should be preferred among older patients. It has therefore
become increasingly clear that (neo)adjuvant therapy con-
cepts for older patients should consider – next to oncological
needs – the patient's physical and functional status, and
should not be determined merely on the basis of their age as
in the ICE trial of the German Breast Group. Otherwise older
patients will continue to be undertreated and will not benefit
from the advances in medicine.
Conclusion
The pooled analysis of a substantial cohort of older primary
breast cancer patients demonstrates that taxane-containing
(neo)adjuvant chemotherapy is feasible in older patients and
that toxicity can be reduced by sequential therapy regimens
and consequent use of prophylactic treatment.
Table 3
Incidence of leukopenia and neutropenia per schedule according to different age intervals
Combination (TAC) 
schedule (n = 450)
Sequence schedule (n = 360) Combination dose-dense 
(ATdd) schedule (n = 121)
Sequence dose-dense schedule (n = 86)
Nontaxane Taxane Nontaxane (dose-
dense epirubicin)
Taxane (dose-
dense paclitaxel)
Leukopenia
Patients aged < 60 years 878 (57.3) 423 (43.4) 419 (47.3) 164 (50.2) 82 (29.2) 7 (2.6)
Patients aged 60 to 64 
years
175 (65.3) 124 (53.9) 107 (51.0) 49 (61.3) 20 (36.4) 0 (0.0)
Patients aged > 64 years 111 (64.9) 99 (60.7) 71 (49.0) 25 (62.5) 17 (42.5) 1 (2.9)
Neutropenia
Patients aged < 60 years 371 (37.5) 455 (52.8) 346 (45.3) 136 (43.5) 74 (29.7) 20 (8.7)
Patients aged 60 to 64 
years
139 (56.7) 106 (52.0) 79 (44.1) 37 (47.4) 18 (36.7) 2 (5.0)
Patients aged > 64 years 91 (55.2) 97 (65.5) 61 (48.4) 17 (43.6) 11 (33.3) 1 (3.2)
Febrile neutropenia
Patients aged < 60 years 140 (9.3) 9 (1.0) 19 (2.5) 14 (4.5) 0 (0.0) 0 (0.0)
Patients aged 60 to 64 
years
30 (11.3) 1 (0.5) 5 (2.8) 4 (5.1) 3 (6.4) 0 (0.0)
Patients aged > 64 years 24 (14.3) 2 (1.4) 1 (0.8) 2 (5.1) 0 (0.0) 0 (0.0)
Data presented as n (%). All percentage values are valid. TAC, docetaxel/doxorubicin/cyclophosphamide; ATdd, doxorubicin/docetaxel dose-dense.Available online http://breast-cancer-research.com/content/10/5/R77
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Table 4
Nonhematologic toxicity per schedule in patients aged ≥ 60 years, n (%)
Docetaxel Paclitaxel Total
Fatigue grade 1 to grade 4
Patients aged <60 years 1,922 (88.4) - 1,922 (88.4)
Patients aged 60 to 64 years 362 (87.0) - 362 (87.0)
Patients aged >64 years 235 (90.4) - 235 (90.4)
P value 0.414 - 0.414
Fatigue grade 3 to grade 4
Patients aged <60 years 315 (14.5) - 315 (14.5)
Patients aged 60 to 64 years 81 (19.5) - 81 (19.5)
Patients aged >64 years 61 (23.5) - 61 (23.5)
P value <0.001 - <0.001
Loss of appetite grade 1 to grade 3
Patients aged <60 years 441 (67.0) - 441 (67.0)
Patients aged 60 to 64 years 110 (73.8) - 110 (73.8)
Patients aged >64 years 76 (84.4) - 76 (84.4)
P value 0.002 - 0.002
Loss of appetite grade 3
Patients aged <60 years 76 (11.6) - 76 (11.6)
Patients aged 60 to 64 years 33 (22.1) - 33 (22.1)
Patients aged >64 years 18 (20.0) - 18 (20.0)
P value 0.001 - 0.001
Nausea/vomiting grade 1 to grade 4
Patients aged <60 years 1,980 (77.5) 473 (84.6) 2,453 (78.8)
Patients aged 60 to 64 years 410 (79.3) 101 (85.6) 511 (80.5)
Patients aged >64 years 290 (85.5) 62 (78.5) 352 (84.2)
P value 0.003 0.337 0.028
Nausea/vomiting grade 3 to grade 4
Patients aged <60 years 206 (8.1) 32 (5.7) 238 (7.6)
Patients aged 60 to 64 years 47 (9.1) 2 (1.7) 49 (7.7)
Patients aged >64 years 34 (10.0) 0 (0.0) 39 (9.3)
P value 0.392 0.175 0.479
Mucositis grade 1 to grade 4
Patients aged <60 years 1,736 (68.0) 299 (53.5) 2,035 (65.4)
Patients aged 60 to 64 years 360 (69.9) 77 (65.3) 437 (69.0)
Patients aged >64 years 231 (68.5) 42 (53.2) 273 (65.6)
P value 0.688 0.060 0.205
Mucositis grade 3 to grade 4
Patients aged <60 years 115 (4.5) 9 (1.6) 124 (4.0)
Patients aged 60 to 64 years 26 (5.0) 7 (5.9) 33 (5.2)
Patients aged >64 years 25 (7.4) 5 (6.3) 30 (7.2)
P value 0.064 0.004 0.007
Sensory neuropathy grade 1 to grade 4Breast Cancer Research    Vol 10 No 5    Loibl et al.
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Patients aged <60 years 39 (1.5) 15 (2.7) 54 (1.7)
Patients aged 60 to 64 years 16 (3.1) 2 (1.7) 18 (2.8)
Patients aged >64 years 6 (1.8) 3 (3.8) 9 (2.2)
P value 0.729 0.803 0.647
Sensory neuropathy grade 3 to grade 4
Patients aged <60 years 39 (1.5) 15 (2.7) 54 (1.7)
Patients aged 60 to 64 years 16 (3.1) 2 (1.7) 18 (2.8)
Patients aged >64 years 6 (1.8) 3 (3.8) 9 (2.2)
P value 0.050 0.662 0.177
Conjunctivitis grade 1 to grade 3
Patients aged <60 years 1,002 (46.1) - 1,002 (46.1)
Patients aged 60 to 64 years 191 (45.9) - 191 (45.9)
Patients aged >64 years 119 (45.9) - 119 (45.9)
P value 0.996 - 0.996
Conjunctivitis grade 3
Patients aged <60 years 25 (1.2) - 25 (1.2)
Patients aged 60 to 64 years 7 (1.7) - 7 (1.7)
Patients aged >64 years 4 (1.5) - 4 (1.5)
P value 0.615 - 0.615
Nail changes grade 1 to grade 3
Patients aged <60 years 849 (39.1) - 849 (39.1)
Patients aged 60 to 64 years 171 (41.3) - 171 (41.3)
Patients aged >64 years 100 (38.8) - 100 (38.8)
P value 0.680 - 0.680
Nail changes grade 3
Patients aged <60 years 22 (1.0) - 22 (1.0)
Patients aged 60 to 64 years 6 (1.4) - 6 (1.4)
Patients aged >64 years 1 (0.4) - 1 (0.4)
P value 0.411 - 0.411
Skin changes grade 1 to grade 4
Patients aged <60 years 1,126 (44.1) 202 (36.1) 1,328 (42.7)
Patients aged 60 to 64 years 221 (42.9) 51 (43.2) 272 (43.0)
Patients aged >64 years 137 (40.8) 25 (31.6) 162 (39.0)
P value 0.479 0.212 0.348
Skin changes grade 3 to grade 4
Patients aged <60 years 43 (1.7) 4 (0.7) 47 (1.5)
Patients aged 60 to 64 years 19 (3.7) 2 (1.7) 21 (3.3)
Patients aged >64 years 12 (3.6) 0 (0.0) 12 (2.9)
P value 0.003 0.388 0.003
Diarrhea grade 1 to grade 4
Patients aged <60 years 1,037 (40.6) 137 (24.5) 1,174 (37.7)
Patients aged 60 to 64 years 219 (42.2) 30 (25.4) 249 (39.3)
Table 4 (Continued)
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Patients aged >64 years 171 (50.6) 13 (16.5) 184 (44.1)
P value 0.002 0.263 0.039
Diarrhea grades 3 to grade 4
Patients aged <60 years 99 (3.9) 7 (1.3) 106 (3.4)
Patients aged 60 to 64 years 24 (4.7) 0 (0.0) 24 (3.8)
Patients aged >64 years 17 (5.0) 0 (0.0) 17 (4.1)
P value 0.482 0.288 0.731
Fluid retention grade 1 to grade 4
Patients aged <60 years 954 (37.4) - 954 (37.4)
Patients aged 60 to 64 years 188 (36.5) - 188 (36.5)
Patients aged >64 years 128 (38.0) - 128 (38.0)
P value 0.898 - 0.898
Fluid retention grade 3 to grade 4
Patients aged <60 years 42 (1.6) - 42 (1.6)
Patients aged 60 to 64 years 7 (1.4) - 7 (1.4)
Patients aged >64 years 4 (1.2) - 4 (1.2)
P value 0.754 - 0.754
Infection with neutropenia grade 1 to grade 4
Patients aged <60 years 174 (16.7) 36 (6.4) 210 (13.1)
Patients aged 60 to 64 years 48 (19.4) 15 (12.5) 63 (17.2)
Patients aged >64 years 35 (21.0) 3 (3.8) 38 (15.4)
P value 0.305 0.029 0.104
Infection with neutropenia grade 3 to grade 4
Patients aged <60 years 21 (2.0) 4 (0.7) 25 (1.6)
Patients aged 60 to 64 years 9 (3.6) 3 (2.5) 12 (3.3)
Patients aged >64 years 8 (4.8) 2 (2.5) 10 (4.1)
P value 0.062 0.129 0.010
Creatinine grade 1 to grade 4
Patients aged <60 years 73 (3.4) 7 (1.3) 80 (3.0)
Patients aged 60 to 64 years 26 (6.3) 5 (4.2) 31 (5.8)
Patients aged >64 years 20 (7.8) 5 (7.0) 25 (7.6)
P value <0.001 0.003 <0.001
Hot flushes grade 1 to grade 3
Patients aged <60 years 425 (64.6) - 425 (64.6)
Patients aged 60 to 64 years 88 (59.1) - 88 (59.1)
Patients aged >64 years 46 (51.1) - 46 (51.1)
P value 0.031 - 0.031
Hot flushes grade 3
Patients aged <60 years 66 (10.0) - 66 (10.0)
Patients aged 60 to 64 years 15 (10.1) - 15 (10.1)
Patients aged >64 years 2 (2.2) - 2 (2.2)
P value 0.053 - 0.053
Table 4 (Continued)
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